Form 4: Armata Pharmaceuticals SVP, Finance, and PFO David Duane House Acquires 75,000 Stock Options

Sentiment:

SEC Form 4 Filing


David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, acquired 75,000 stock options on October 2, 2024.

Summary

  • On October 2, 2024, David Duane House, the SVP, Finance, and PFO of Armata Pharmaceuticals, acquired 75,000 stock options.
  • The exercise price of these options is $2.32.
  • The options vest 25% on August 16th of each of 2025, 2026, 2027, and 2028, contingent upon continuous service through each vesting date.
  • The expiration date for these options is October 2, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports the acquisition of stock options by a company officer, which could be seen as a positive sign of confidence, but without further context, it's difficult to assess the overall impact.

Positives

  • The acquisition of stock options by a high-ranking officer may indicate confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities.

Stakeholder Impact

  • Shareholders may view the acquisition of stock options by a company officer as a positive sign.

Key Dates

DateDescription
10/02/2024Date of the transaction: acquisition of 75,000 stock options.
08/16/2025First vesting date: 25% of the options vest.
08/16/2026Second vesting date: 25% of the options vest.
08/16/2027Third vesting date: 25% of the options vest.
08/16/2028Fourth vesting date: 25% of the options vest.
10/02/2034Expiration date of the stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.